A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 201–300 of 1,008
Alzheimer's Disease Genetics Consortium, Wetzel-Smith, M. K., Hunkapiller, J., Bhangale, T. R., Srinivasan, K., Maloney, J. A., Atwal, J. K., Sa, S. M., B Yaylaoglu, M., Foreman, O., et al. (2014) · Nature Medicine · doi:10.1038/nm.3736 · Cited by 153
Self-citationLate-Onset Alzheimer’s Disease Genes and the Potentially Implicated Pathways
Rosenthal, S. L., & Kamboh, M. I. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0034-x · Cited by 153
Udayar, V., Buggia-Prévot, V., Guerreiro, R. L., Siegel, G., Rambabu, N., Soohoo, A. L., Ponnusamy, M., Siegenthaler, B., Bali, J., Guerreiro, R., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.12.005 · Cited by 147
“, 2003) and in certain forms of sporadic AD (Jonsson et al., 2012), we propose that the Rab11-mediated recycling route represents a drug target for AD, which is supported by our exome-sequencing results and the unbiased PPI network analysis.”
ResultAung, T., Ozaki, M., Lee, M., Schlötzer-Schrehardt, U. M., Þorleifsson, G., Mizoguchi, T., Igo, R. P., Haripriya, A., Williams, S. E. I., Astakhov, Y. S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3875 · Cited by 161
Myhre, O., Utkilen, H., Duale, N., Brunborg, G., & Hofer, T. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/726954 · Cited by 152
“Unlike this genotype, a rare APP mutation positioned close to the site where β-secretase cleaves APP into amyloid-β leads to reduced formation of Aβ peptide monomers and protection against AD [27].”
BackgroundLannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt246 · Cited by 153
“A recent finding of a protective mutation in the AβPP gene (A673T) resulted in reduced β-secretase cleavage of AβPP as well as a lowered risk of developing sporadic AD and slowing of the rate of cognitive decline in an older population [13], further strengthening the amyloid hypothesis.”
BackgroundMan, V. H., Nguyen, P. H., & Derreumaux, P. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b04689 · Cited by 153
Yuzwa, S. A., Shan, X., Jones, B. A., Zhao, G., Woodward, M. L., Li, X., Zhu, Y., McEachern, E. J., Silverman, M. A., Watson, N. V., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-42 · Cited by 152
“Furthermore, some mutations in APP also confer protection against AD [7].”
BackgroundAlzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
Herskowitz, J. H., Feng, Y., Mattheyses, A. L., Hales, C. M., Higginbotham, L. A., Duong, D. M., Montine, T. J., Troncoso, J. C., Thambisetty, M., Seyfried, N. T., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2508-13.2013 · Cited by 150
“Moreover, genetic studies in a population of Icelanders indicated that an APP amino acid substitution that abrogates cleavage by BACE1 protects against AD (Jonsson et al., 2012).”
BackgroundHitt, B., Riordan, S. M., Kukreja, L., Eimer, W. A., Rajapaksha, T. W., & Vassar, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.415505 · Cited by 143
Ciurea, A. V., Mohan, A. G., Covache-Busuioc, R.-A., Costin, H. P., Glavan, L.-A., Corlatescu, A.-D., & Saceleanu, V. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310809 · Cited by 172
“[17] on a population of 1795 Icelandic subjects.”
BackgroundHaass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
Benilova, I., Gallardo, R., Ungureanu, A.-A., Castillo Cano, V., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J., & De Strooper, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599027 · Cited by 145
“These authors provided evidence that the Ala-to-Thr substitution decreased -secretase cleavage of APP and therefore the generation of A peptide with about 40% in a cell line (21).”
BackgroundResultInfluentialGenomics of Alzheimer Disease: A Review
Rosenberg, R. N., Lambracht-Washington, D., Yu, G., & Xia, W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0301 · Cited by 146
Physiology and pharmacology of amyloid precursor protein
Cho, Y., Bae, H.-G., Okun, E., Arumugam, T. V., & Jo, D.-G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108122 · Cited by 142
Buchholz, S., & Zempel, H. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13784 · Cited by 137
“263 Remarkably, a homozygous mutation in APOE ɛ 3 (R136S, “Christchurch”), identified in one individual with an inherited PSEN1 variant,protectedagainstneurodegenerationandcognitivedeclinefor decades after the expected onset of disease symptoms.”
BackgroundAmyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis
Lucey, B. P., & Bateman, R. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.035 · Cited by 144
Stem cell models of Alzheimer’s disease: progress and challenges
Arber, C., Lovejoy, C., & Wray, S. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0268-4 · Cited by 143
“The A673T mutation in APP leads to a reduced likelihood of contracting AD [81].”
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 155
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 160
Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus
Desikan, R. S., Schork, A. J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L. K., Holland, D., Brewer, J. B., Chen, C.-H., Thompson, W. K., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.6 · Cited by 148
Self-citationGamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J.-F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 137
Lee, M.-C., Yu, W.-C., Shih, Y.-H., Chen, C.-Y., Guo, Z.-H., Huang, S.-J., Chan, J. C. C., & Chen, Y.-R. (2018) · Scientific Reports · doi:10.1038/s41598-018-23122-x · Cited by 134
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
Menting, K. W., & Claassen, J. A. H. R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00165 · Cited by 139
Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis
Dong, S., Duan, Y., Hu, Y., & Zhao, Z. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-18 · Cited by 139
“Interestingly, a recently identified mutation adjacent to β-site (A673T) of APP gene was shown to result in Aβ reduction and protection against cognitive decline in the elderly without AD [22].”
BackgroundExome sequencing and complex disease: practical aspects of rare variant association studies
Do, R., Kathiresan, S., & Abecasis, G. R. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds387 · Cited by 137
Jeppsson, F., Eketjäll, S., Janson, J., Karlström, S., Gustavsson, S., Olsson, L.-L., Radesäter, A.-C., Ploeger, B., Cebers, G., Kolmodin, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409110 · Cited by 139
“Recently, discovery of a variant of the APP gene (APPA673T) at a site proximal to the BACE1 proteolytic site that confers protection against AD was reported (22).”
BackgroundBushman, D. M., Kaeser, G. E., Siddoway, B., Westra, J. W., Rivera, R. R., Rehen, S. K., Yung, Y. C., & Chun, J. (2015) · eLife · doi:10.7554/elife.05116 · Cited by 136
“with an APP partial loss-of-function mutation (Jonsson et al., 2012).”
BackgroundInfluentialCOVID-19 and Alzheimer’s disease: how one crisis worsens the other
Xia, X., Wang, Y., & Zheng, J. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00237-2 · Cited by 153
“The Aβ hypothesis is supported by findings from genetics: (1) familial AD mutations of APP and PSEN1/2, transcripts encoding two key components of the γ-secretase complex, are involved in either Aβ generation or Aβ processing and result in excessive production of Aβ40–42 [33]; conversely, an APP missense mutation (A67…”
BackgroundYuan, J., Venkatraman, S., Zheng, Y., McKeever, B. M., Dillard, L. W., & Singh, S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301659n · Cited by 135
Common and low-frequency variants associated with genome-wide recombination rate
Kong, A., Þorleifsson, G., Frigge, M. L., Másson, G., Gudbjartsson, D. F., Villemoes, R., Magnúsdóttir, E., Olafsdottir, S. B., Þorsteinsdóttir, U., & Stefánsson, K. (2013) · Nature Genetics · doi:10.1038/ng.2833 · Cited by 149
Self-citationβ-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 132
“A rare mutation in the Iceland population gave a strong evidence for the important role of Aβ in the pathomechanism of AD [18].”
BackgroundProtective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
“, identified a missense mutation within the APP gene in an elderly Icelandic population that was both protective against Alzheimer’s disease and associated with a slower decline in cognitive function among cognitively normal individuals [21, 42].”
BackgroundInfluentialMaking the final cut: Pathogenic amyloid-β peptide generation by γ-secretase
Steiner, H., Fukumori, A., Tagami, S., & Okochi, M. (2018) · Cell Stress · doi:10.15698/cst2018.11.162 · Cited by 133
“Interestingly, another mutation close to the β-secretase cleavage site that lowers Aβ levels and protects against AD has been identified in the Icelandic population [23].”
BackgroundKostylev, M. A., Kaufman, A. C., Nygaard, H. B., Patel, P., Haas, L. T., Gunther, E. C., Vortmeyer, A., & Strittmatter, S. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643577 · Cited by 133
“Substantial human genetic data along with in vivo and in vitro experimental studies highlight a key role of amyloid-β peptide (Aβ) in triggering AD pathogenesis (6-8).”
BackgroundRamanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
“Mutations in APP are among the causes of early-onset Alzheimer’s disease (Bettens et al., 2013) and a rare variant in APP was found to be protective against late-onset Alzheimer’s disease (Jonsson et al., 2012).”
BackgroundYang, J., Zhang, X., Yuan, P., Yang, J., Xu, Y., Grutzendler, J., Shao, Y., Moore, A., & Ran, C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706248114 · Cited by 135
“The prevalent drug development strategies, which are largely predicated on amyloid and tau hypotheses, have not been successful in delivering effective treatment (1, 2).”
The genetic landscape of Alzheimer disease
Carmona, S., Hardy, J., & Guerreiro, R. J. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00026-0 · Cited by 155
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Eketjäll, S., Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J., Haeberlein, S. B., Kugler, A. R., Alexander, R. C., & Cebers, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150834 · Cited by 132
“Conversely, individuals who express A PP with the A673T substitution are protected against AD and cognitive decline; the substitution reduces A production [9, 10].”
BackgroundPharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions
Filser, S., Ovsepian, S. V., Masana, M., Blázquez‐Llorca, L., Elvang, A. B., Volbracht, C., Müller, M. B., Jung, C. K. E., & Herms, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.013 · Cited by 150
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E.-K., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 125
Protective alleles and modifier variants in human health and disease
Harper, A. R., Nayee, S., & Topol, E. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg4017 · Cited by 141
BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis
Zhang, S., Wang, Z., Cai, F., Zhang, M., Wu, Y., Zhang, J., & Song, W. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0340-17.2017 · Cited by 129
“…missense mutation of alanine to threonine on the same residue (A673T) in the Icelandic population, in contrast, was protective against AD development (Jonsson et al., 2012), suggesting that the amino acid at position 673 of APP might be critical for BACE1 cleavage site selection for APP processing.”
BackgroundHirdes, J. P., van Everdingen, C., Ferris, J., Franco-Martin, M., Fries, B. E., Heikkilä, J., Hirdes, A., Hoffman, R., James, M. L., Martin, L., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00926 · Cited by 124
Genetics of Alzheimer’s Disease
Vilatela, M. E. A., López, M., & Yescas, P. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.017 · Cited by 165
Synaptic dysfunction and septin protein family members in neurodegenerative diseases
Marttinen, M., Kurkinen, K. M., Soininen, H., Haapasalo, A., & Hiltunen, M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0013-z · Cited by 130
“These studies identified a potential protective mutation in APP [25,26].”
BackgroundInfluentialUnderstanding Amyloid Fibril Nucleation and Aβ Oligomer/Drug Interactions from Computer Simulations
Nguyen, P. H., & Derreumaux, P. (2013) · Accounts of Chemical Research · doi:10.1021/ar4002075 · Cited by 131
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M. A., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 126
“On the other hand, it was reported that a mutation in the APP gene (A673T), identified from a set of whole-genome sequence data of 1795 Iceland people, results in a lifelong decrease in APP cleavage by β-secretase conferring a reduced clinical risk of AD and age-related decline [19,20].”
BackgroundThe Hippocampus in Neurodegenerative Disease
Moodley, K. K., & Chan, D. (2014) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000356430 · Cited by 142
Genetic markers for diagnosis and pathogenesis of Alzheimer's disease
Kim, D., Yeo, S. H., Park, J.-M., Choi, J. Y., Lee, T.-H., Park, S. Y., Ock, M. S., Eo, J., Kim, H., & Cha, H. (2014) · Gene · doi:10.1016/j.gene.2014.05.031 · Cited by 146
Jones, S. V., & Kounatidis, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01805 · Cited by 127
“APP is cleaved by the beta-secreatase BACE1 into amyloid monomers that form oligomers that eventually become plaques in the brain and vasculature.”
BackgroundInfluentialHu, X., Das, B., Hou, H., He, W., & Yan, R. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171831 · Cited by 130
“Genetic mutations such as the K670M671 to N670L671 mutation (Mullan et al., 1992) or the A673 to T673 mutation (Jonsson et al., 2012) can either increase or decrease Aβ generation, resulting in early-onset AD or protection against developing AD.”
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“In contrast, a protective mutation in APP (A673T) identified in the Icelandic population (Jonsson et al., 2012) results in approximately a 40% reduction in the formation of amyloidogenic peptides.”
BackgroundBACE inhibition-dependent repair of Alzheimer’s pathophysiology
Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708106114 · Cited by 125
“Strong support for the relevance of our findings comes from genetic studies showing that human carriers of the A673T mutation, which reduces the enzymatic activity of BACE, are protected against AD (33), whereas humans with the Swedish mutation, which enhances BACE activity, develop AD at an early age (34).”
ResultKoelsch, G. (2017) · Molecules · doi:10.3390/molecules22101723 · Cited by 125
“The activity the aminopeptidase activity that generates Aβ3-x substrates for glutaminyl cyclase might be impacted by the Ala to Thr change in the P1 position of A673T-generated Aβ.”
BackgroundInfluentialCampion, D., Charbonnier, C., & Nicolas, G. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01991-4 · Cited by 124
Shen, Y., Wang, H., Sun, Q., Yao, H., Keegan, A. P., Mullan, M., Wilson, J., Lista, S., Leyhe, T., Laske, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.007 · Cited by 123
“Moreover, a rare mutation close to the BACE1 cleavage site in the APP gene that protects against cognitive decline and the risk of developing AD substantially supports the hypothesis that BACE1 plays a key role in AD pathogenesis (21).”
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
Role of BACE1 in Alzheimer’s synaptic function
Das, B., & Yan, R. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0093-5 · Cited by 121
The Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
Zhang, X., Fu, Z., Meng, L., He, M., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00359 · Cited by 122
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques
Pensalfini, A., Albay, R., Rasool, S., Wu, J. W., Hatami, A., Arai, H., Margol, L., Milton, S., Poon, W. W., Corrada, M. M., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.011 · Cited by 120
Long noncoding RNAs in aging and age-related diseases
Kour, S., & Rath, P. C. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.001 · Cited by 127
The keystone of Alzheimer pathogenesis might be sought in Aβ physiology
Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116
Precise and efficient scarless genome editing in stem cells using CORRECT
Kwart, D., Paquet, D., Teo, S., & Tessier‐Lavigne, M. (2017) · Nature Protocols · doi:10.1038/nprot.2016.171 · Cited by 129
Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 114
The dendritic hypothesis for Alzheimer's disease pathophysiology
Cochran, J. N., Hall, A. M., & Roberson, E. D. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.12.004 · Cited by 114
“Furthermore, a protective variant in one of these genes, APP, can reduce the risk of late-onset, sporadic AD [105].”
BackgroundAre N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 114
“Thus, all mutations responsible for early onset and aggressive forms of AD share as common denominators a modulation of total A load, modification of A 42 over the A 40 ratio, or generate A species prone to aggregation (9, 10).”
BackgroundSperling, R., Henley, D., Aisen, P. S., Raman, R., Donohue, M. C., Ernstrom, K., Rafii, M. S., Streffer, J., Shi, Y., Karcher, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4857 · Cited by 112
Ganesan, D., & Cai, Q. (2021) · Biochemical Journal · doi:10.1042/bcj20200917 · Cited by 131
International Parkinson’s Disease Genetics Consortium (IPGDC), Jansen, I. E., Ye, H., Heetveld, S., Lechler, M. C., Michels, H., Seinstra, R. I., Lubbe, S. J., Drouet, V., Lesage, S., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1147-9 · Cited by 117
“Despite recent successes in other neurodegenerative disease with complex genetic etiologies, including Alzheimer ’ s disease [10 – 12] and amyotrophic lateral sclerosis [13, 14], sequencing has yet to be deployed in large, unrelated PD case/control samples for rare variant discovery.”
The therapeutics of Alzheimer's disease: Where we stand and where we are heading
Selkoe, D. J. (2013) · Annals of Neurology · doi:10.1002/ana.24001 · Cited by 113
“Furthermore, Lilly has announced it will begin another large ( 2,100 subject) phase III trial of solanezumab confined to mild AD.”
ResultInfluentialAlzheimer’s Disease: Etiology, Neuropathology and Pathogenesis
Sheppard, O., & Coleman, M. P. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch1 · Cited by 205
“Interestingly, studies have also found that there is an APP mutation (Icelandic—A673T) which lowers Aβ and protects against AD (31).”
BackgroundAPOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease
Vélez, J. I., Lopera, F., Sepulveda-Falla, D., Patel, H. R., Johar, A. S., Chuah, A., Tobón, C., Rivera, D., Villegas, A., Cai, Y., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.177 · Cited by 111
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 101
“In a notable recent discovery, Jonsson and colleagues discovered a rare mutation (A673T) in the APP gene that was protective against Alzheimer’s disease [29].”
BackgroundA Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-β Protein 42 Levels
Lee, M., Guo, J.-P., Kennedy, K., McGeer, E. G., & McGeer, P. L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160748 · Cited by 112
Alzheimer's disease in the omics era
Sancesario, G. M., & Bernardini, S. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.06.011 · Cited by 113
Alzheimer's disease in Down syndrome: an overlooked population for prevention trials
Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J., Levin, J., Nuebling, G., Rebillat, A., Ritchie, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.006 · Cited by 110
“Targeting this mechanism is further supported by the finding that an Icelandic mutation that reduces the production of amyloidogenic species via the processing of APP is protective against AD [16].”
BackgroundToward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress
Gandy, S., & DeKosky, S. T. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092611-084441 · Cited by 110
“A recent discovery that an APP mutation that inhibits BACE cleavage may be protective against AD will undoubtedly fuel enthusiasm for BACE inhibitors (73) as well as strengthen the hypothesis that amyloid mis-metabolism is a primary cause of AD.”
BackgroundRhodium‐Catalyzed Hydrocarboxylation of Olefins with Carbon Dioxide
Kawashima, S., Aikawa, K., & Mikami, K. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201600338 · Cited by 110
Deng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9375 · Cited by 108
Use of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition
Baig, M. H., Ahmad, K., Rabbani, G., & Choi, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00021 · Cited by 104
“This hypothesis was further reinforced by the identification of a protective amyloid precursor protein (APP) mutation near the protein’s beta-cleavage site, which protects against the development of late onset dementia (Jonsson et al., 2012).”
BackgroundNew Mouse Model of Alzheimer’s
Nilsson, P., Saito, T., & Saido, T. C. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500105p · Cited by 107
Pharmacogenomics in clinical practice and drug development
Harper, A. R., & Topol, E. J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2424 · Cited by 106
Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein
Ben Halima, S., Mishra, S., Raja, K. M. P., Willem, M., Baici, A., Simons, K., Brüstle, O., Koch, P., Haass, C., Caflisch, A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.076 · Cited by 105
Mullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Novak, G., Streffer, J. R., Timmers, M., Henley, D., Brashear, H. R., Bogert, J., Russu, A., Janssens, L., Tesseur, I., Tritsmans, L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00614-5 · Cited by 107
Prokopenko, D., Morgan, S. L., Mullin, K., Hofmann, O., Chapman, B., Kirchner, R., (ADNI), A. D. N. I., Amberkar, S., Wohlers, I., Lange, C., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12319 · Cited by 105
“In contrast, common loci associated with AD 22 have been enriched significantly in microglia (Figure 7).”
Coronel, R., Bernabeu-Zornoza, A., Palmer, C., Moreno, M. D. M. M., Zambrano, A., Cano, E., & Liste, I. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0914-2 · Cited by 117
“A new, rare, mutation encoding an alanine-to-threonine substitution at residue 673 (A673T) in the APP gene has been identified, which confers protection against development of AD and cognitive decline [89].”
Ulamec, S. M., Brockwell, D. J., & Radford, S. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.611285 · Cited by 112
Roussos, P., Katsel, P., Fam, P., Tan, W., Purohit, D. P., & Haroutunian, V. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.013 · Cited by 103
“The same cohort was also genotyped for a rare missense mutation (rs63750847) at the APP gene [30].”
BackgroundVitek, M. P., Araujo, J. A., Fossel, M., Greenberg, B. D., Howell, G. R., Rizzo, S. J. S., Seyfried, N. T., Tenner, A. J., Territo, P. R., Windisch, M., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12114 · Cited by 103
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
“This suggests that it is not the amount of A generated but post-cleavage processing that might be contributing to the differences between plaque formation (perhaps a beneficial factor to rid the brain of the soluble forms of A ) and processed soluble species (perhaps oxidized forms) in causing dementia [44, 45].”
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Heneka, M. T., Morgan, D., & Jessen, F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01883-x · Cited by 126
Advances in development of fluorescent probes for detecting amyloid-β aggregates
Xu, M., Ren, W., Tang, X.-C., Hu, Y., & Zhang, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.155 · Cited by 113
Izzo, N. J., Yuede, C. M., LaBarbera, K. M., Limegrover, C. S., Rehak, C., Yurko, R., Waybright, L., Look, G., Rishton, G., Safferstein, H., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12302 · Cited by 95
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.